iBio, Inc., Newark, announced the issuance of additional patents in the US and Europe.
“These patents strengthen patent protection for commercial activities we are engaged in to improve the yield and functional properties of antibody products,” stated Robert Erwin, iBio’s president. “Some product candidates are intended to address opportunities in Brazil and we expect to commercialize those via our subsidiary company, iBio do Brasil Biofarmaceutical Ltda., while others are expected to be of interest to commercial partners in the U.S., Europe, and/or Japan.”
iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and similar diseases using its iBioLaunch platform that extracts material from plants..
In Brazil, iBio has formed a subsidiary company and has been collaborating with the Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a yellow fever vaccine based on iBio technology.
The iBioLaunch gene expression platform is a technology for development and production of biologics using green plants.
The iBioModulator platform complements the iBioLaunch gene expression platform and is designed to improve vaccine products.
iBio stock has risen to about $1 a share, after dropping below 50 cents in January. Shares briefly rose to $3 in October amid speculation that its platform could be used to produce Ebola vaccine.
The plant-based platform has the potential to produce vaccines more quickly than through the use of eggs and other proteins.
Further information is available at: www.ibioinc.com.
